Welcome to our dedicated page for Coeptis Therapeutics Holdings SEC filings (Ticker: COEPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Coeptis Therapeutics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Coeptis Therapeutics Holdings's regulatory disclosures and financial reporting.
Coeptis Therapeutics Holdings, Inc. officer Christine Elise Sheehy, VP Compliance and Secretary, increased her direct holdings of common stock through compensation-related transactions. On February 11, 2026, she exercised stock options to acquire 1,000 shares of common stock at an exercise price of $10.56 per share, reflecting the cost to convert her options into shares.
On the same date, she also acquired 12,500 shares of restricted common stock at $0 per share as part of an option exchange program in which underwater options were surrendered for restricted stock. After these transactions, she directly beneficially owned 64,031 shares of Coeptis common stock.
Coeptis Therapeutics Holdings, Inc. implemented a one-time option repricing and exchange program for options under its 2022 Equity Incentive Plan, covering officers and directors. Holders could either reprice underwater options or surrender them for restricted stock, and all options were made fully vested.
Several executives, including CEO David Mehalick, exchanged underwater options for an equal number of restricted shares and exercised remaining vested options to receive restricted common stock. The company also received notice from Nasdaq that it has regained compliance with the annual meeting requirement, so its Nasdaq Capital Market listing is no longer at risk from that issue.
Coeptis Therapeutics Holdings, Inc. reported the results of its Annual and Special Meeting of Stockholders held on January 30, 2026. Stockholders considered nine proposals described in the company’s proxy statement.
A quorum was present, with 3,697,558 shares represented out of 5,680,111 shares of common stock outstanding as of the January 2, 2026 record date. Multiple proposals received strong support, with several “FOR” vote totals above 3.45 million shares versus materially smaller “AGAINST” and abstention counts.
Stockholders also voted on the election of five directors. Bryan Fuerst, Adam Sohn, David Halabu, Michelle Burke, and Kenneth Cooper each received approximately 3.69 million “FOR” votes, with very few votes withheld and no broker non-votes reported. An adjournment proposal related to Proposals 1–8 was listed as Proposal 9 but was not presented at the meeting.
The Vanguard Group has disclosed a significant ownership position in Coeptis Therapeutics Holdings Inc common stock. Vanguard reports beneficial ownership of 339,486 shares, representing 6.35% of the outstanding common stock, with shared voting power over 26,244 shares and shared dispositive power over 339,486 shares.
The Vanguard Total Stock Market Index Fund Investor Shares is separately reported as beneficially owning 268,093 shares, or 5.02% of the class, with sole voting power over those shares. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries will report beneficial ownership on a disaggregated basis. The filing certifies that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Coeptis.
Coeptis Therapeutics Holdings, Inc. is asking stockholders to approve a transaction that would merge Z Squared into Coeptis, issue Coeptis common stock as merger consideration and change the combined company's name to "Z Squared Inc." The proxy/prospectus seeks approvals for the Merger, a Spin Out of certain biopharmaceutical operations (excluding GEAR Therapeutics, Inc.), an amendment to the certificate of incorporation, a new equity incentive plan, election of the combined company's board, repricing or replacement of certain outstanding options, and potential adjournment to solicit additional proxies.
The filing includes a fairness opinion from Sun Business Valuations LLC dated May 12, 2025, a $5.0 million potential termination fee, disclosure that Z Squared will contribute 9,000 cryptocurrency mining machines (recorded at historical carrying value), and a preliminary goodwill/intangible asset adjustment of $63,075,231. The pro forma information shows historical losses for both entities and an explicit statement that there is "substantial doubt" about going concern. The Merger is subject to customary closing conditions including SEC effectiveness, Nasdaq continued listing, regulatory consents, and stockholder approvals.